Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PETS 
PetMed Express Inc (PETS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: PETS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Year Target Price $3.6
Year Target Price $3.6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.78% | Avg. Invested days 42 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.58M USD | Price to earnings Ratio 332 | 1Y Target Price 3.6 |
Price to earnings Ratio 332 | 1Y Target Price 3.6 | ||
Volume (30-day avg) 2 | Beta 0.81 | 52 Weeks Range 2.90 - 6.85 | Updated Date 06/30/2025 |
52 Weeks Range 2.90 - 6.85 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.01 |
Earnings Date
Report Date 2025-06-09 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin 0.15% | Operating Margin (TTM) -0.85% |
Management Effectiveness
Return on Assets (TTM) 0.93% | Return on Equity (TTM) 0.36% |
Valuation
Trailing PE 332 | Forward PE 17.92 | Enterprise Value 19799001 | Price to Sales(TTM) 0.28 |
Enterprise Value 19799001 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 0.08 | Enterprise Value to EBITDA 2.63 | Shares Outstanding 20656500 | Shares Floating 13992261 |
Shares Outstanding 20656500 | Shares Floating 13992261 | ||
Percent Insiders 29.38 | Percent Institutions 40.63 |
Analyst Ratings
Rating 2 | Target Price 3.6 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
PetMed Express Inc
Company Overview
History and Background
PetMed Express, Inc., founded in 1996, is a leading online pet pharmacy. It provides prescription and non-prescription pet medications, health and nutritional supplements, and pet supplies directly to consumers.
Core Business Areas
- Pet Medications: Sale of prescription and non-prescription medications for dogs and cats.
- Health and Nutritional Supplements: Sale of vitamins, supplements, and other health products for pets.
- Pet Supplies: Sale of various pet supplies, including food, treats, and accessories.
Leadership and Structure
The leadership team includes Matt Hulett (CEO) and Christine Chambers (CFO). The organizational structure is typical for a publicly traded company, with a board of directors and various operational departments.
Top Products and Market Share
Key Offerings
- Flea & Tick Medications: Includes brands like Frontline, Advantage, and Revolution. Competitors are Chewy, Amazon, and local vets. Revenue is significant but specific figures are difficult to extract from public information without estimates.
- Heartworm Preventatives: Includes brands like Heartgard and Interceptor. Competitors are Chewy, Amazon, and local vets. Revenue is significant but specific figures are difficult to extract from public information without estimates.
- Arthritis & Pain Medications: Includes brands like Rimadyl and Deramaxx. Competitors are Chewy, Amazon, and local vets. Revenue is significant but specific figures are difficult to extract from public information without estimates.
Market Dynamics
Industry Overview
The pet medication market is experiencing growth, driven by increasing pet ownership and a focus on pet health. Online retailers are gaining market share.
Positioning
PetMed Express is a well-established online pet pharmacy with a focus on prescription medications. Competitive advantages include brand recognition and a large customer base.
Total Addressable Market (TAM)
The global pet care market is estimated to be around $300 billion. PetMed Express captures a small percentage of this market.
Upturn SWOT Analysis
Strengths
- Established brand recognition
- Large customer base
- Direct-to-consumer model
- Focus on prescription medications
Weaknesses
- Dependence on manufacturer relationships
- Competition from larger online retailers
- Marketing spend efficiency
- Fluctuations in new customer acquisition
Opportunities
- Expanding product offerings
- International expansion
- Strategic partnerships
- Growth in telehealth for pets
Threats
- Increased competition
- Changes in regulations
- Economic downturn
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- CHWY
- AMZN
- VETZ
Competitive Landscape
PetMed Express faces intense competition from larger online retailers like Chewy and Amazon. It needs to differentiate itself through service or specialized offerings.
Growth Trajectory and Initiatives
Historical Growth: PetMed Express has experienced fluctuating growth rates in recent years, with revenue growth slowing down.
Future Projections: Analysts project moderate growth for PetMed Express, contingent on new initiatives and market conditions.
Recent Initiatives: Recent initiatives focus on improving marketing efficiency and customer retention.
Summary
PetMed Express is facing increasing competition from larger online retailers, and revenue growth has slowed. While the company maintains a strong brand presence, efficiency in marketing and customer retention are needed for future success. Fluctuating financials and suspended dividends is a cause for concern, and the company must aggressively pursue new strategic initiatives to remain competitive. Growth in telehealth and improved marketing could offer avenues for success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PetMed Express Inc
Exchange NASDAQ | Headquaters Delray Beach, FL, United States | ||
IPO Launch date 1999-04-26 | President, CEO & Director Ms. Sandra Y. Campos | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 287 | Website https://www.1800petmeds.com |
Full time employees 287 | Website https://www.1800petmeds.com | ||
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.